A new study revealed that Mimmanin, which is used to treat Alzheimer’s patients, may help treat adolescents with autism to enhance their communication skills.
Scientists have previously indicated that taking a daily medication may be effective in helping people with autism to improve their behaviors, such as the difficulty of visual communication, hyperactivity, and understanding of feelings.
The study was conducted by researchers from the Massachusetts General Hospital in Boston in the United States, and the results were published in Gamma Oben Network on October 1, and the Daily Mail was written about it.
Researchers who follow dozens of American adolescents with autism showed that more than half of those who took the medicine, which slows the deterioration of the brain function and protects its cells, witnessed an improvement in their social media skills, in contrast, only five of those who took the imaginary medicine were noticed with the same effect.
Experts pointed out that the drug may be an effective therapeutic option for a large percentage of autistic patients, but they warned of the need to conduct more research first to prove this.
Mimanin medicine
Mimmanin, also known as the commercial name Empixa, is originally used to treat Alzheimer’s disease, and it has been agreed to use it among patients of the National Health Services in the United Kingdom who do not respond to other treatments.
The drug works by blocking the effects of chemical glutamate in the brain, which is believed to be associated with the development of dementia.
“The possibility of the response of young people who received two -time treatment for treatment is 4.8 times compared to imaginary treatment,” said scientists from Massachusetts General Hospital in Boston.
Mimmanin was acceptable for young people with autism without mental disability, and was associated with a noticeable improvement in autism behaviors.
And they continued: “This result also indicates that Mimanin may be a relatively effective therapeutic option, which may lead to better results in a large percentage of patients.”